Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1442-1450. doi: 10.6004/jnccn.2018.7074.

PMID:
30545991
2.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
3.

The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.

Pleiman JK, Irving AA, Wang Z, Toraason E, Clipson L, Dove WF, Deming DA, Newton MA.

PLoS Genet. 2018 Sep 6;14(9):e1007611. doi: 10.1371/journal.pgen.1007611. eCollection 2018 Sep.

4.

Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.

Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F.

J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28.

5.

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Foley TM, Payne SN, Pasch CA, Yueh AE, Van De Hey DR, Korkos DP, Clipson L, Maher ME, Matkowskyj KA, Newton MA, Deming DA.

Mol Cancer Res. 2017 Feb 9;15(3):317-327. doi: 10.1158/1541-7786.MCR-16-0256. [Epub ahead of print]

6.

Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates.

Sievers CK, Zou LS, Pickhardt PJ, Matkowskyj KA, Albrecht DM, Clipson L, Bacher JW, Pooler BD, Moawad FJ, Cash BD, Reichelderfer M, Vo TN, Newton MA, Larget BR, Halberg RB.

Gut. 2017 Dec;66(12):2132-2140. doi: 10.1136/gutjnl-2016-312232. Epub 2016 Sep 8.

7.

Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon.

Sievers CK, Leystra AA, Clipson L, Dove WF, Halberg RB.

Cancer Prev Res (Phila). 2016 Aug;9(8):638-41. doi: 10.1158/1940-6207.CAPR-16-0096. Epub 2016 May 19.

8.

Molecular Profiles Guide Colorectal Cancer Treatment.

Kratz JD, Turk AA, Sievers CK, Clipson L, Matkowskyj KA, Deming DA.

Fed Pract. 2016 May;33(Suppl 4):50S-53S.

9.

Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.

Hadac JN, Miller DD, Grimes IC, Clipson L, Newton MA, Schelman WR, Halberg RB.

Anticancer Res. 2016 Mar;36(3):845-52.

10.

Advanced Intestinal Cancers often Maintain a Multi-Ancestral Architecture.

Zahm CD, Szulczewski JM, Leystra AA, Paul Olson TJ, Clipson L, Albrecht DM, Middlebrooks M, Thliveris AT, Matkowskyj KA, Washington MK, Newton MA, Eliceiri KW, Halberg RB.

PLoS One. 2016 Feb 26;11(2):e0150170. doi: 10.1371/journal.pone.0150170. eCollection 2016.

11.

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.

Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA.

PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016.

12.

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.

Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA.

Oncogenesis. 2015 Oct 5;4:e169. doi: 10.1038/oncsis.2015.28.

13.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA.

Ther Adv Med Oncol. 2015 Sep;7(5):252-62. doi: 10.1177/1758834015591952. Review.

14.

Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Hadac JN, Leystra AA, Paul Olson TJ, Maher ME, Payne SN, Yueh AE, Schwartz AR, Albrecht DM, Clipson L, Pasch CA, Matkowskyj KA, Halberg RB, Deming DA.

Cancer Prev Res (Phila). 2015 Oct;8(10):952-61. doi: 10.1158/1940-6207.CAPR-15-0003. Epub 2015 Aug 14.

15.

Improved Detection of Microsatellite Instability in Early Colorectal Lesions.

Bacher JW, Sievers CK, Albrecht DM, Grimes IC, Weiss JM, Matkowskyj KA, Agni RM, Vyazunova I, Clipson L, Storts DR, Thliveris AT, Halberg RB.

PLoS One. 2015 Aug 7;10(8):e0132727. doi: 10.1371/journal.pone.0132727. eCollection 2015.

16.

Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer.

Irving AA, Plum LA, Blaser WJ, Ford MR, Weng C, Clipson L, DeLuca HF, Dove WF.

J Nutr. 2015 Feb;145(2):291-8. doi: 10.3945/jn.114.204396. Epub 2014 Dec 24.

17.

Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones.

Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V, Hommes DW, Shedlovsky A, Dove WF, van den Brink GR.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16514-9. doi: 10.1073/pnas.1323064111. Epub 2014 Nov 3.

18.

The utility of Apc-mutant rats in modeling human colon cancer.

Irving AA, Yoshimi K, Hart ML, Parker T, Clipson L, Ford MR, Kuramoto T, Dove WF, Amos-Landgraf JM.

Dis Model Mech. 2014 Nov;7(11):1215-25. doi: 10.1242/dmm.016980. Epub 2014 Oct 2. Review.

19.

Phospholipid ether analogs for the detection of colorectal tumors.

Deming DA, Maher ME, Leystra AA, Grudzinski JP, Clipson L, Albrecht DM, Washington MK, Matkowskyj KA, Hall LT, Lubner SJ, Weichert JP, Halberg RB.

PLoS One. 2014 Oct 6;9(10):e109668. doi: 10.1371/journal.pone.0109668. eCollection 2014.

20.

A strategy to identify dominant point mutant modifiers of a quantitative trait.

Dove WF, Shedlovsky A, Clipson L, Amos-Landgraf JM, Halberg RB, Krentz KJ, Boehm FJ, Newton MA, Adams DJ, Keane TM.

G3 (Bethesda). 2014 Apr 17;4(6):1113-21. doi: 10.1534/g3.114.010595.

21.

A simple, quantitative method using alginate gel to determine rat colonic tumor volume in vivo.

Irving AA, Young LB, Pleiman JK, Konrath MJ, Marzella B, Nonte M, Cacciatore J, Ford MR, Clipson L, Amos-Landgraf JM, Dove WF.

Comp Med. 2014 Apr;64(2):128-34.

22.

Dynamic tumor growth patterns in a novel murine model of colorectal cancer.

Paul Olson TJ, Hadac JN, Sievers CK, Leystra AA, Deming DA, Zahm CD, Albrecht DM, Nomura A, Nettekoven LA, Plesh LK, Clipson L, Sullivan R, Newton MA, Schelman WR, Halberg RB.

Cancer Prev Res (Phila). 2014 Jan;7(1):105-13. doi: 10.1158/1940-6207.CAPR-13-0163. Epub 2013 Nov 6.

23.

Transformation of epithelial cells through recruitment leads to polyclonal intestinal tumors.

Thliveris AT, Schwefel B, Clipson L, Plesh L, Zahm CD, Leystra AA, Washington MK, Sullivan R, Deming DA, Newton MA, Halberg RB.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11523-8. doi: 10.1073/pnas.1303064110. Epub 2013 Jun 24.

24.

PIK3CA and APC mutations are synergistic in the development of intestinal cancers.

Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, Halberg RB.

Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27.

25.

mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.

Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB.

PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013.

26.

Regulated Expression of Chromobox Homolog 5 Revealed in Tumors of Apc(Min) (/+) ROSA11 Gene Trap Mice.

Thliveris AT, Clipson L, Sommer LL, Schoenike BA, Hasenstein JR, Schlamp CL, Alexander CM, Newton MA, Dove WF, Amos-Landgraf JM.

G3 (Bethesda). 2012 May;2(5):569-78. doi: 10.1534/g3.112.002436. Epub 2012 May 1.

27.

Mice expressing activated PI3K rapidly develop advanced colon cancer.

Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, Halberg RB.

Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23.

28.

The many ways to open the gate to colon cancer.

Amos-Landgraf JM, Clipson L, Newton MA, Dove WF.

Cell Cycle. 2012 Apr 1;11(7):1261-2. doi: 10.4161/cc.19888. Epub 2012 Apr 1. No abstract available.

29.

Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms.

Amos-Landgraf JM, Irving AA, Hartman C, Hunter A, Laube B, Chen X, Clipson L, Newton MA, Dove WF.

Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2060-5. doi: 10.1073/pnas.1120753109. Epub 2012 Jan 23.

30.

Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models.

Irving AA, Halberg RB, Albrecht DM, Plum LA, Krentz KJ, Clipson L, Drinkwater N, Amos-Landgraf JM, Dove WF, DeLuca HF.

Arch Biochem Biophys. 2011 Nov;515(1-2):64-71. doi: 10.1016/j.abb.2011.08.011. Epub 2011 Sep 1.

31.

Clonal structure of carcinogen-induced intestinal tumors in mice.

Thliveris AT, Clipson L, White A, Waggoner J, Plesh L, Skinner BL, Zahm CD, Sullivan R, Dove WF, Newton MA, Halberg RB.

Cancer Prev Res (Phila). 2011 Jun;4(6):916-23. doi: 10.1158/1940-6207.CAPR-11-0022.

32.

Long-lived Min mice develop advanced intestinal cancers through a genetically conservative pathway.

Halberg RB, Waggoner J, Rasmussen K, White A, Clipson L, Prunuske AJ, Bacher JW, Sullivan R, Washington MK, Pitot HC, Petrini JH, Albertson DG, Dove WF.

Cancer Res. 2009 Jul 15;69(14):5768-75. doi: 10.1158/0008-5472.CAN-09-0446. Epub 2009 Jul 7.

33.

Cyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substrates.

Halberg RB, Larsen MC, Elmergreen TL, Ko AY, Irving AA, Clipson L, Jefcoate CR.

Cancer Res. 2008 Sep 15;68(18):7394-402. doi: 10.1158/0008-5472.CAN-07-6750.

34.

The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.

Halberg RB, Chen X, Amos-Landgraf JM, White A, Rasmussen K, Clipson L, Pasch C, Sullivan R, Pitot HC, Dove WF.

Genetics. 2008 Sep;180(1):601-9. doi: 10.1534/genetics.108.091967. Epub 2008 Aug 24.

35.

Widespread hyperplasia induced by transgenic TGFalpha in ApcMin mice is associated with only regional effects on tumorigenesis.

Bilger A, Sullivan R, Prunuske AJ, Clipson L, Drinkwater NR, Dove WF.

Carcinogenesis. 2008 Sep;29(9):1825-30. doi: 10.1093/carcin/bgn038. Epub 2008 Feb 28.

36.

Reproducibility of tumor volume measurement at microCT colonography in living mice.

Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, Weichert JP, Pickhardt PJ, Halberg RB.

Acad Radiol. 2008 Mar;15(3):334-41. doi: 10.1016/j.acra.2007.10.005.

37.

Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18.

Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WF.

Genetics. 2007 Jun;176(2):1237-44. Epub 2007 Apr 15.

38.

A statistical test of the hypothesis that polyclonal intestinal tumors arise by random collision of initiated clones.

Newton MA, Clipson L, Thliveris AT, Halberg RB.

Biometrics. 2006 Sep;62(3):721-7.

PMID:
16984313
39.

Polyclonality of familial murine adenomas: analyses of mouse chimeras with low tumor multiplicity suggest short-range interactions.

Thliveris AT, Halberg RB, Clipson L, Dove WF, Sullivan R, Washington MK, Stanhope S, Newton MA.

Proc Natl Acad Sci U S A. 2005 May 10;102(19):6960-5. Epub 2005 May 3.

40.

A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice.

Shoemaker AR, Moser AR, Midgley CA, Clipson L, Newton MA, Dove WF.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10826-31.

41.

Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status.

Dove WF, Clipson L, Gould KA, Luongo C, Marshall DJ, Moser AR, Newton MA, Jacoby RF.

Cancer Res. 1997 Mar 1;57(5):812-4.

42.

Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation.

Moser AR, Shoemaker AR, Connelly CS, Clipson L, Gould KA, Luongo C, Dove WF, Siggers PH, Gardner RL.

Dev Dyn. 1995 Aug;203(4):422-33.

43.

Teratocarcinoma transplantation antigens are encoded in the H-2 region.

Johnson LL, Clipson LJ, Dove WF, Feilbach J, Maher LJ, Shedlovsky A.

Immunogenetics. 1983;18(2):137-45.

PMID:
6350173
44.

Strong teratocarcinoma transplantation loci, Gt-1 and Gt-2, flank H-2.

Shedlovsky A, Clipson LJ, VandeBerg JL, Dove WF.

Immunogenetics. 1981;13(5):413-9.

PMID:
7298086

Supplemental Content

Loading ...
Support Center